Login / Signup

Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.

Zhonghua LiuMichelle WilliamsJohn StewartBonnie S GlissonClifton FullerSinchita Roy-Chowdhuri
Published in: Cancer cytopathology (2021)
PD-L1 expression in HNSCC cytology samples has high concordance with paired histologic samples. PD-L1 CPS evaluation is feasible in HNSCC cytology CBs and can act as a surrogate for determining eligibility for immunotherapy in cases in which a histologic specimen is not readily available.
Keyphrases
  • fine needle aspiration
  • high grade
  • ultrasound guided
  • poor prognosis
  • binding protein
  • mesenchymal stem cells
  • cell therapy
  • clinical evaluation